as nasdaq juno 1 industry biotechnology founded 2013 2 headquarters seattle wa key people hans bishop ceo & president steve harr m.d. cfo hyam levitsky m.d. cso mark gilbert m.d. cmo website junotherapeutics.com juno therapeutics is a biopharmaceutical company founded in 2013 through a collaboration of the fred hutchinson cancer research center memorial sloan kettering cancer center and pediatrics partner seattle children s research institute . the company was launched with an initial investment of 120 million with a remit to develop a pipeline of cancer immunotherapy drugs . 2 the company raised 300 million through private funding and a further 265 million through their ipo . company history edit in december 2014 the company signed an agreement with opus bio inc for a chimeric antigen receptor car t cell product candidate targeting cd22 . 3 in april 2015 the company entered into a collaboration with medimmune a subsidiary of astra zeneca investigating combination treatments for cancer . the trials will assess combinations of medi4736 and one of juno s cd19 directed chimeric antigen receptor t cell candidates . 4 in may 2015 the company announced its intention to acquire stage cell therapeutics for up to 223 million . 5 later in the same month the company launched a collaboration with editas medicine to create car t and high affinity t cell receptor therapies to treat cancer with the potential to generate up to 737 million plus for editas . 6 in june the company announced it would acquire x body for more than 44 million . 7 in june the company announced a 10 year partnership with celgene valued at 1 billion . 8 as part of the deal celgene will pay juno 150 million and acquire 9.1 million new juno shares valued at 93 existing juno shares rose 26 % to 58.38 . celgene will gain the right to sell juno s therapies around the world . this partnership surpasses the previous highest record when pfizer agreed to a deal with merck kgaa in 2014 . 9 in january 2016 juno announced it had acquired abvitro allowing it to use next generation single cell sequencing platforms to complement its ability to create t cells engineered to target a broad array of cancer targets . 10 later in july of the same year the company announced it would acquire redoxtherapies for 10 million . 11 in august the company announced it would license rights from memorial sloan kettering cancer center and eureka therapeutics for a novel fully human binding domain targeting b cell maturation antigen . 12 pipeline edit drug notes jcar014 targeted at cd19 . currently in phase i ii trials at the fred hutchison cancer research center tested for relapsed or refractory chronic lymphocytic leukemia non hodgkin s lymphoma and acute lymphoblastic leukemia . 13 jcar015 targeted at cd19 . 14 designed to treat acute lymphoblastic leukemia all . in 2014 in phase i trials with memorial sloan kettering cancer centre ; received orphan drug designation by fda in november 2014 . 15 in 2016 was in phase ii trial for all . 14 jcar017 targeted at cd19 . currently in phase i ii trials at seattle children s hospital tested for pediatric and young adult relapsed refractory cd19 positive leukemia . 16 jtcr016 targeted at wt 1 . currently in phase i for adult acute myeloid leukemia . 17 jcar023 targeted at l1cam . currently in phase i for pediatric neuroblastoma . 17 jcar018 targeted at cd22.currently in phase i for non hodgkin s lymphoma and acute lymphoblastic leukemia . 17 others two more in phase i by mid 2016 . 17 references edit news release . juno therapeutics . a b news release . juno therapeutics . news release . juno therapeutics . medimmune juno team up to study cancer immunotherapy combo . gen. juno therapeutics buys stage cell therapeutics for up to 233m . gen. staff may 27 2015 . juno editas launch up to 737m cancer therapy collaboration . genetic engineering & biotechnology news . retrieved 2016 02 11 . juno therapeutics acquires x body for 44m . gen. celgene launches 1b immunotherapy collaboration with juno . gen. doni bloomfield 29 june 2015 . juno rises as celgene pays 1 billion to buy cancer stake . bloomberg.com . http www.genengnews.com gen news highlights juno s abvitro acquisition adds sequencing to repertoire 81252218 http www.genengnews.com gen news highlights juno buys redoxtherapies for 10m 81252959 http www.genengnews.com gen news highlights juno licenses bcma from msk eureka therapeutics 81253053 laboratory treated t cells in treating patients with relapsed or refractory chronic lymphocytic leukemia non hodgkin lymphoma or acute lymphoblastic leukemia . clinicaltrials.gov . a b juno seeks trial protocol change following patient deaths . july 2016 juno s jcar015 leukemia t cell therapy granted orphan drug designation by fda . juno therapeutics . 18 nov 2014 . a pediatric and young adult trial of genetically modified t cells directed against cd19 for relapsed refractory cd19 leukemia . clinicaltrials.gov . a b c d pipeline . juno therapeutics . retrieved from https en.wikipedia.org w index.php title juno therapeutics & oldid 742534412 categories biopharmaceutical companiescompanies listed on nasdaqpharmaceutical companies established in 2013 navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages add links this page was last modified on 4 october 2016 at 08 00 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view